Great Point Partners LLC Sells 855,263 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Great Point Partners LLC decreased its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 55.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 674,075 shares of the company’s stock after selling 855,263 shares during the period. Vistagen Therapeutics makes up 0.6% of Great Point Partners LLC’s portfolio, making the stock its 27th largest holding. Great Point Partners LLC owned approximately 2.42% of Vistagen Therapeutics worth $2,029,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. American Century Companies Inc. lifted its stake in shares of Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after buying an additional 9,984 shares during the period. Blair William & Co. IL raised its stake in shares of Vistagen Therapeutics by 29.2% in the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Valence8 US LP bought a new position in Vistagen Therapeutics in the third quarter worth $103,000. Institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Stock Down 4.6 %

NASDAQ VTGN opened at $2.60 on Wednesday. Vistagen Therapeutics, Inc. has a 1-year low of $2.48 and a 1-year high of $5.86. The stock’s 50 day moving average is $2.97 and its two-hundred day moving average is $3.40.

Analyst Ratings Changes

Separately, William Blair raised shares of Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.